Sign In
Buy INCY
$115.09
+0.210 (+0.183%)
At Close: Jul 15, 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types.
2 Fast-Growing Pharmaceutical Stocks to Buy Now
08:05pm, Wednesday, 08'th Jul 2026
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.
Incyte to Report Second Quarter Financial Results
08:00am, Wednesday, 08'th Jul 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 202
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio.
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion
11:58am, Friday, 03'rd Jul 2026
Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year.
Dow Taps Record as Nasdaq, Chips Pull Back
11:47am, Thursday, 02'nd Jul 2026
Stocks are trading mixed as chip stocks weigh and investors digest a fresh batch of June nonfarm payrolls data
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
02:41pm, Monday, 29'th Jun 2026
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
10:55am, Monday, 29'th Jun 2026
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Incyte: New Catalysts Support Another Leg Higher
08:35am, Monday, 29'th Jun 2026
Incyte Corporation remains a strong long pick, with a maintained 'Buy' rating and a 40% upside to a $159.5/share price target. Recent catalysts include a positive CHMP opinion for Opzelura in Europe a
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis.
Futures are trading mixed as we prepare to finish the last full week of the second quarter.
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
10:51am, Friday, 19'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or Refractory DLBCL.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
07:51am, Wednesday, 17'th Jun 2026
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
